Segall Bryant & Hamill LLC Has $20.33 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Segall Bryant & Hamill LLC raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 355,176 shares of the biopharmaceutical company's stock after buying an additional 49,856 shares during the period. Segall Bryant & Hamill LLC owned about 0.28% of Halozyme Therapeutics worth $20,330,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Congress Asset Management Co. boosted its stake in Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock valued at $139,298,000 after acquiring an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB grew its stake in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock worth $112,715,000 after purchasing an additional 856,200 shares during the period. Dimensional Fund Advisors LP increased its holdings in Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after purchasing an additional 209,530 shares during the last quarter. Epoch Investment Partners Inc. lifted its stake in Halozyme Therapeutics by 23.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,433,612 shares of the biopharmaceutical company's stock valued at $58,319,000 after buying an additional 270,579 shares during the period. Finally, American Century Companies Inc. boosted its holdings in Halozyme Therapeutics by 9.7% during the second quarter. American Century Companies Inc. now owns 821,266 shares of the biopharmaceutical company's stock worth $43,002,000 after buying an additional 72,544 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at $9,254,244.56. This trade represents a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 60,000 shares of company stock valued at $3,425,000 in the last 90 days. 2.40% of the stock is currently owned by insiders.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $45.76 on Thursday. The stock's 50-day simple moving average is $55.15 and its 200 day simple moving average is $53.48. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. The company has a market cap of $5.82 billion, a P/E ratio of 15.15, a P/E/G ratio of 0.41 and a beta of 1.29.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HALO. HC Wainwright reaffirmed a "buy" rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday. JMP Securities upped their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research note on Friday, November 1st. TD Cowen lifted their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a "buy" rating in a research report on Wednesday, August 7th. Wells Fargo & Company downgraded Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their price objective for the stock from $58.00 to $62.00 in a research note on Monday, October 7th. Finally, Benchmark reissued a "buy" rating and issued a $60.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $61.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.